gefurulimab   Click here for help

GtoPdb Ligand ID: 14698

Synonyms: ALXN-1720 | ALXN1720 | CON-9978 | Klygefa® | TPP-2511
Immunopharmacology Ligand
Compound class: Antibody
Comment: Gefurulimab (ALXN1720) is a bispecific VHH nanobody that binds complement component C5 (in the terminal complement cascade) and serum albumin [1]. It is designed to block enzymatic cleavage of C5 (into biologically active C5a and C5b fragments), and reduce inflammation. Binding to serum albumin extends the agent's systemic half-life and therapeutic window.
References
1. Jindal S, Pedersen DV, Gera N, Chandler J, Patel R, Neill A, Cone J, Zhang Y, Yuan CX, Millman EE et al.. (2024)
Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration.
Mol Immunol, 165: 29-41. [PMID:38142486]
2. White LM, Clay FJ, Forbes AM, Keh RYS, Lilleker JB, Spillane J, Storms K, Sussman J, Dodd KC. (2025)
Complement inhibitors for myasthenia gravis in adults.
Cochrane Database Syst Rev, 7 (7): CD016098. [PMID:40626411]